Literature DB >> 21864282

Development of 5-Fluorouracil derivatives as anticancer agents.

Xiaoyan Pan1, Chen Wang, Fang Wang, Pengfei Li, Zhigang Hu, Yuanyuan Shan, Jie Zhang.   

Abstract

5-Fluorouracil (5-FU) is one of the most potent antimetabolites which have been widely used in the treatment of advanced solid tumors. As an anticancer agent, because of its low efficacy and high toxicity, numerous modifications of 5-FU structure have been performed. A great number of novel 5-FU derivatives have been developed with highly efficient and much less toxic. In this paper, the recent development of novel 5-FU derivatives as potent antitumor agents is reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864282     DOI: 10.2174/092986711797287584

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity.

Authors:  Francesco Imperi; Francesco Massai; Marcella Facchini; Emanuela Frangipani; Daniela Visaggio; Livia Leoni; Alessandra Bragonzi; Paolo Visca
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

2.  Acyclic nucleoside phosphonates containing the amide bond.

Authors:  Iwona E Głowacka; Dorota G Piotrowska; Graciela Andrei; Dominique Schols; Robert Snoeck; Andrzej E Wróblewski
Journal:  Monatsh Chem       Date:  2016-10-26       Impact factor: 1.451

3.  In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies.

Authors:  Aristote Matondo; Washington Dendera; Bienfait Kabuyaya Isamura; Koto-Te-Nyiwa Ngbolua; Hilaire V S Mambo; Mayaliwa Muzomwe; Virima Mudogo
Journal:  Adv Appl Bioinform Chem       Date:  2022-08-15

4.  Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.

Authors:  Masahiro Hiratsuka; Hiroshi Yamashita; Fumika Akai; Hiroki Hosono; Eiji Hishinuma; Noriyasu Hirasawa; Takahiro Mori
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.